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INTRODUCTION Blinding
Patients, investigators and study centres maintained strict blinding throughout the study. The centre recruitment codes were placed in opaque envelopes. They were all returned and none had been opened during the trial. The omeprazole and placebo capsules were identical in appearance.
Compliance
Patient compliance was checked by counting the returned study medication. A priori, non-compliance was defined as an intake of less than 75% of the medication during the study period. The administration of all drugs during the study period was recorded.
Symptom and quality of life assessment
This was undertaken at baseline and at the end of the trial, at the 4 week visit.
Symptoms.
The primary outcome assessment was measurement of gastrointestinal symptoms. Epigastric pain and/or discomfort during the 3 days prior to the first and last visits in the trial was recorded by the physician. Symptoms were graded by the investigator at interview on a four-point Likert scale as follows: 0(none), no symptoms; 1(mild), awareness of the symptom but easily tolerated; 2(moderate), symptoms sufficient to cause an interference with normal activities; 3(severe), incapacitating symptoms with an inability to perform normal activities. This scale has been shown to be responsive and valid in reflux disease 18 and functional dyspepsia. 19, 20 Complete absence of epigastric pain and discomfort on each of the 3 days was the primary end-point.
At the final visit, the patient was interviewed by a physician and asked whether the study medication had provided sufficient control of symptoms, to estimate global patient satisfaction with the treatment.
At the first visit, the patient also ranked his or her three most bothersome symptoms from the following choices: epigastric pain, heartburn, acid regurgitation, bloating, belching, rectal flatus, nausea, early satiety, and postprandial fullness, as defined by the Rome criteria. 1 The patients were then subdivided into the following a priori symptom subgroups based on symptom predominance:
Ulcer-like dyspepsia-predominant epigastric pain.
Dysmotility-like dyspepsia-predominant discomfort (postprandial fullness, early satiety, bloating or belching).
Reflux-like dyspepsia-predominant reflux symptoms (heartburn or acid regurgitation).
Other-predominant nausea or rectal flatus.
Patients recorded their epigastric pain or discomfort on daily diary cards during the 4 week treatment period, where symptoms were self-rated as present or absent.
Quality of life.
Quality of life was assessed using two standard and validated self-report questionnaires: General Well Being Index (PGWB) . This measures subjective well-being or distress. 21, 22 It includes 22 items which can be combined into a global score that ranges from a maximum of 132 to a minimum of 22. Six-point Likert scales comprise the response format, with higher values denoting better well-being. The PGWB has been applied in studies of dyspepsia and gastro-oesophageal reflux disease; there are extensive normative data available. 21, 22 (b) The Gastrointestinal Symptom Rating Scale (GSRS). This has 15 items that measure gastrointestinal symptoms on seven-point Likert scales over the prior 2 weeks, and can be combined into a total score. 21, 22 The lower the score the better the symptom status. The GSRS is valid and responsive, and substantial normative data are available. 21, 22 
Statistical analysis
The primary efficacy variable, i.e. complete relief of epigastric pain/discomfort, was defined as having no symptoms during the last 3 days of the 4 weeks of treatment. The proportion of patients with complete relief of epigastric pain/discomfort was compared between omeprazole 20 mg and 10 mg vs.
placebo using both an intention-to-treat (ITT) and a per protocol (PP) approach. Secondary efficacy variables were analysed using an ITT approach only.
Efficacy of omeprazole in functional dyspepsia: double-blind, randomi... http://onlinelibrary.wiley.com/doi/10.1046/j. 1365-2036.1998.00410.x/full The number needed to treat (the number of patients who need to be treated to prevent a poor outcome) and the relative risk reduction (the proportional reduction in event rates between control and experimental patients) were calculated.
A Mantel-Haenzel chi-squared test with stratification based on countries was used to analyse the difference between the two treatment groups with respect to the primary efficacy variable. The significance level was adjusted for two comparisons using the Bonferroni inequality. Confidence intervals were computed for the proportions and the differences between the treatment groups.
For the secondary efficacy variable, i.e. sufficient control of symptoms, confidence intervals were computed for the proportions and the differences between the treatment groups. The change in total score of the PGWB and mean item score of the GSRS from baseline to the 4-week visit were evaluated. Differences between treatments regarding the quality of life questionnaires were analysed with the baseline scores as a covariate. 
RESULTS
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The progress through the trials is summarized in Figure 1 , which shows the number of eligible patients who were randomized, the numbers withdrawn, and the numbers who completed the trial in each arm.
Baseline comparisons and compliance
The three treatment groups were well balanced regarding all baseline characteristics in both trials (Table 1) . Compliance was excellent; more than 90% of capsules were taken by 86, 87 and 83% of patients, respectively, in the omeprazole 20 mg, omeprazole 10 mg and placebo arms.
Relief of dyspepsia
In the intention-to-treat analysis, complete symptom relief was observed in 38.2% (161/421) on omeprazole 20 mg and 36.0% (146/405) on omeprazole 10 mg, compared with 28.2% (119/422) on placebo in the combined studies. The difference between omeprazole 20 mg and placebo, and between omeprazole 10 mg and placebo, was statistically significant (95% CI: 3.7-16.4% and 1.4-14.3%, respectively). The per protocol analysis yielded essentially the same results (Table 2 ). Comparing omeprazole 20 mg with placebo, the number needed to treat (NNT) was 10 (95% CI: 6-27) and the relative risk reduction was 14.0% (95% CI: 5.3-21.9%). Details from the individual studies are given in Table 2 . Sufficient control of symptoms by an intention-to-treat analysis was reported by 61% on omeprazole 20 mg (95% CI: 55.7-65.3%) compared with 59% on omeprazole 10 mg (95% CI: 54.3-64.1%) and 51% on placebo (95% CI: 46.3-56.0%) in the combined studies. Corresponding figures for the Bond study were 57% on omeprazole 20 mg (95% CI: 50.2-63.7%), 63% on omeprazole 10 mg (95% CI: 56.2-69.9%) and 44% on placebo (95% CI: 37.6-51.1%) and for the Opera study, 64% on omeprazole 20 mg (95% CI: 57.3-71.0%), 55% on omeprazole 10 mg (95% CI: 48.1-62.2%) and 59% on placebo (95% CI: 51.5-65.5%).
Omeprazole 20 mg and 10 mg provided a significantly higher proportion of symptom-free days (52.3 and 50.3%) than placebo (45.5%) over the treatment period in the combined studies. The difference between placebo and omeprazole 20 mg was 6.85% (95% CI: 2.64-11.07%) and for omeprazole 10 mg was 4.84% (95% CI: 0.59-9.10%). Symptoms improved to their maximum level by 7 days; the placebo response did not decrease over the 4 weeks of therapy.
Symptom subgroups
In patients on omeprazole 20 mg, omeprazole 10 mg and placebo, those with ulcer-like dyspepsia (708 patients) had complete symptom relief in 40, 35 and 27% of cases, respectively (P = 0.006 omeprazole 20 mg vs. placebo and P = 0.08 omeprazole 10 mg vs. placebo), while those with reflux-like Efficacy of omeprazole in functional dyspepsia: double-blind, randomi... http://onlinelibrary.wiley.com/doi/10.1046/j. 1365-2036.1998 .00410.x/full dyspepsia (143 patients) had complete relief in 54, 45 and 23% of cases, respectively (P = 0.002 omeprazole 20 mg vs. placebo and P = 0.02 omeprazole 10 mg vs. placebo). In contrast, those with dysmotility-like dyspepsia (291 patients) had complete relief on omeprazole 20 mg, omeprazole 10 mg and placebo in 32, 37 and 31% of cases, respectively (P = 0.92 omeprazole 20 mg vs. placebo and P = 0.33 omeprazole 10 mg vs. placebo) and for patients with other symptoms (i.e. nausea, flatus) (106 patients) the corresponding figures were 25, 30 and 38%, respectively (P = 0.25 omeprazole 20 mg vs. placebo and P = 0.46 omeprazole 10 mg vs. placebo).
H. pylori
A total of 41% of patients (507/1222) were H. pylori-positive by the 13 C-urea breath test. Complete relief of dyspepsia in the active treatment arms was not significantly different between the H. pylori infected and uninfected patients (Table 3) .
Quality of life
The total GSRS score improved from 2.67 to 2.02 on omeprazole 20 mg, from 2.74 to 2.08 on omeprazole 10 mg and from 2.75 to 2.17 on placebo. The difference between omeprazole 20 mg and placebo was statistically significant (P = 0.02, with baseline GSRS as a covariate), but the difference between omeprazole 10 mg and placebo was not (P = 0.08).
The total PGWB score improved similarly in all groups by the last visit. There was no statistically significant difference in the total score or in the subscale scores between the three treatment arms (data not shown).
Treatment response in the Bond vs. Opera studies
The difference in treatment response between active treatment and placebo was greater in the Bond than in the Opera study (Table 4) . This difference was statistically significant when comparing active treatment (omeprazole 20 mg or omeprazole 10 mg) with placebo (P = 0.006) as well as when comparing each active drug with placebo (P = 0.04 for omeprazole 20 mg vs. placebo and P = 0.005 for omeprazole 10 mg vs. placebo). The distribution of the dyspepsia subgroups was similar in the Bond and Opera studies. However, in patients recruited by a general practitioner the difference in treatment response between active treatment and placebo was considerably greater than in patients recruited by a specialist. In the Bond study, 34% of the patients were from family practice but in the Opera study only 8% were from this setting. When adjusting for the type of investigator (family physician or specialist) the differences between the studies in treatment response between active treatment and placebo was no longer statistically significant.
Adverse events
The number of adverse events was low and was similar across the three treatment arms. A total of 34 patients discontinued treatment due to adverse events (10 on omeprazole 20 mg, 9 on omeprazole 10 mg and 15 on placebo). Drugs that reduce gastric acid secretion are commonly prescribed for patients with functional dyspepsia, but their efficacy has been questioned. 12, 14 Randomized placebo-controlled trials of H 2 -receptor antagonists in functional dyspepsia have produced conflicting results; in the positive studies the benefit over placebo was small based on the symptom scores applied and therefore of questionable clinical significance, 14, 23, 24 while the negative trials were often underpowered to detect an important difference between drug and placebo. 14, 25 A meta-analysis suggested that H 2 -blockers produced a therapeutic effect of 20% over placebo but the report has been criticized for only including some of the available trials. 26 Thus, it remains to be definitely established that this class of antisecretory compounds is superior to placebo in functional dyspepsia. On the other hand, the role of more potent acid fficacy of omeprazole in functional dyspepsia: double-blind, randomi... http://onlinelibrary.wiley.com/doi/10.1046/j. 1365-2036.1998 .00410.x/full von 14 12.05.2015 11:53 suppression has not until now been adequately investigated. We found in the present study that omeprazole was superior to placebo in relieving the symptoms of functional dyspepsia, although the benefit was very modest. We combined the results of the two trials because they were of identical design, with the exception that different countries recruited the patients. Rather than relying on an arbitrary symptom score which may not translate into a clinically meaningful number, the main outcome measure in this trial chosen a priori was the most rigorous possible, namely absence of epigastric pain and discomfort. Importantly, all the symptom measures improved in parallel and both doses of omeprazole were superior to placebo. The evidence is consistent with the observed small therapeutic gain with omeprazole being clinically meaningful.
It has been suggested that patients with functional dyspepsia can usefully be divided into subgroups based on symptoms. In the original proposal, ulcer-like, dysmotility-like, reflux-like and non-specific dyspepsia were identified based on clusters of symptoms, 27 and subsequently the Rome criteria were developed along similar lines, although reflux-like dyspepsia was discarded. 1 However, symptom clusters have appeared to be a dismal failure because of substantial symptom overlap and a lack of correlation with pathophysiological disturbances. 2, 3, 8 Hence, in the present study we a priori applied a new forced choice classification based on symptom predominance. We also did not discard reflux symptoms because these are so common in patients with any upper gastrointestinal tract disease including peptic ulceration. 28 We noted that the symptom benefit with omeprazole was greatest in patients with ulcer-like or reflux-like dyspepsia, and was not observed in those with dysmotility-like symptoms. The results suggest that symptom subgrouping based on symptom predominance has clinical utility because it predicts treatment response.
There are very few other trials that have addressed the clinical benefit of proton pump inhibitor therapy in functional dyspepsia. Lauritsen and co-workers randomized 197 patients with functional dyspepsia to omeprazole 20 mg twice daily or placebo for 2 weeks in Denmark and Sweden; complete relief of dyspepsia in the last 2 days was observed in 35% on omeprazole and 13% on placebo, which was a significant difference. 19 On the other hand, a German multicentre study randomized 801 patients with functional dyspepsia to omeprazole (10 mg and 20 mg daily), ranitidine (150 mg nightly) or placebo for 2 weeks. 29 The investigator judged whether the patient required further investigation or treatment, and using this as the primary end-point there was no significant difference between the groups.
There are other studies that have evaluated proton pump inhibitor therapy in uninvestigated dyspepsia in primary care. Meineche-Schmidt & Krag reported a randomized trial of omeprazole (20 mg daily) and placebo for 2 weeks in 536 Danish patients with no documented history of ulcer or gastrooesophageal reflux disease but who had ulcer-like or reflux-like dyspepsia; 50% on omeprazole compared with 35% on placebo had no symptoms at the end of the trial. 30 Another trial enrolled 674 patients with uninvestigated dyspepsia and/or heartburn and in an open-label study randomized them to omeprazole 10 mg daily or Gaviscon four times daily for 4 weeks; symptom abolition at 4 weeks was observed in 41% on omeprazole and 16% on
Gaviscon, but although statistically significant, the results are very difficult to interpret because of the lack of blinding. 31 Jones & Baxter in a randomized trial compared lansoprazole 30 mg daily with ranitidine 150 mg twice daily; the proton pump inhibitor provided significant symptom relief compared with the H 2 -antagonist in those with epigastric pain and/or heartburn, but patients with and without a history of structural disease were enrolled and no placebo control group was included. 32
A recent systematic review of all published randomized controlled trials in functional dyspepsia evaluated a total of 52 eligible studies; 33 the majority of trials suffered from serious weaknesses in study design and execution, and only five studies used previously validated outcome measures. In this trial careful attention was given to avoiding previously identified methodological concerns. In particular, validated outcome measures were utilized, strict blinding was maintained, an adequate placebo control was included and the study was sufficiently powered to detect modest but clinically significant differences. Utilizing the hard end-point of symptom absence, the placebo response was minimized. Hence our results suggest that a subgroup of patients with functional dyspepsia are responsive to acid suppression, and we conclude that the findings are likely to be accurate and applicable in clinical practice.
If proton pump inhibitors are efficacious in some patients with functional dyspepsia, by what mechanism do they reduce symptoms? Modulation of gastric acid secretion is one consideration. Earlier reports demonstrated that both basal and peak acid output were similar in patients with functional dyspepsia compared with appropriate control groups. 10 More recent work has shown that acid secretion in response to gastrin-releasing peptide (GRP) was significantly increased in H. pylori infected patients with functional dyspepsia compared to H. pylori-positive healthy volunteers. 11 Overall, approximately 50% of patients with functional dyspepsia had a disturbance of GRP-stimulated acid secretion and in this group the disturbance was similar to that found in patients with duodenal ulcer. 11 The data suggest that a subset of patients with functional dyspepsia and. H. pylori infection have acid dysregulation that potentially may respond to acid suppression. However, in the present trial, H. pylori status did not predict response to therapy so that this mechanism appears unlikely to explain the results.
A further possible explanation for the efficacy of omeprazole in functional dyspepsia may relate to undiagnosed gastro-oesophageal reflux disease (GERD). Heartburn is a very common complaint in the general population; 34 furthermore, the majority of patients with functional dyspepsia have co-existent heartburn if specific enquiries are made. 35 It is conceivable that some patients labelled by their physician as having functional dyspepsia in this trial actually had atypical GERD and this may explain any benefit of acid suppression. 36, 37 Indeed, while the majority of patients enrolled had ulcer-like dyspepsia (n = 708 or 56%), 143 patients (11%) were classified at entry as having predominant reflux symptoms and it is likely that true pathological acid reflux was present in a subset of these patients. The rate of complete symptom relief observed in reflux-like dyspepsia in this trial was similar to the symptom relief of heartburn observed in patients with endoscopy-negative GERD. 38 On the other hand, in the present study patients with endoscopically diagnosed oesophagitis, a past history of documented GERD or heartburn alone were excluded. Moreover, patients had to have a diagnosis of functional dyspepsia based on the investigators, judgement in order to enter the trial. While 24 h oesophageal pH testing would have provided additional information to address how many patients had true gastro-oesophageal reflux, it is invasive and would have resulted in a highly selected patient population being enrolled because of refusals, and hence was considered impractical. Moreover, other work suggests that acid exposure as measured by 24 h oesophageal pH testing does not predict the response to proton pump inhibitor therapy in dyspepsia. 19 In practice this is not a crucial 1 issue as our results show that a subset of patients with a clinical and endoscopic diagnosis of functional dyspepsia will respond to omeprazole. However, more research is required to determine if atypical GERD explains the benefit of acid suppression in some patients with functional dyspepsia.
We did observe a lower treatment effect in Study 2 compared to the Bond study. This could not be explained by baseline differences and for this reason it was justifiable to combine the studies. More general practitioners participated in the Bond study whereas a higher proportion of gastroenterologists participated in the Opera study. Interestingly, the placebo response was higher amongst those patients seeing a gastroenterologist (32%) compared to those enrolled by a family practitioner (13%), although the response to active treatment was reasonably similar in both groups (Table 4) . Conceivably, those seeing a specialist may feel more reassured that they do not have a serious underlying disease, which may promote a higher placebo response.
In conclusion, our results have demonstrated that the proton pump inhibitor omeprazole at a dose of 20 mg and 10 mg was modestly superior to placebo in relieving the symptoms of functional dyspepsia, particularly in those with ulcer-like or reflux-like dyspepsia, but symptom relief was similar in those with and without H. pylori infection.
